Antibody-drug conjugate · Cytotoxic, directed at T-cell immunoglobulin mucin-1 (TIM-1) (HAVCR1) · developed by Celldex Therapeutics
CDX-014 is an antibody-drug conjugate in which a human IgG1 antibody (clone CR014) binds the extracellular domain of TIM-1 (HAVCR1), linked by a valine-citrulline peptide linker to the cytotoxic agent monomethyl auristatin E (MMAE). After internalization and cleavage, MMAE is released into TIM-1-expressing tumor cells, where it inhibits microtubule polymerization. It is studied in renal cell carcinoma and ovarian clear cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02837991 | Phase 1 | Renal Cell Carcinoma (RCC) | Terminated | CLDX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Clear-cell Renal Cell CarcinomaKidney NeoplasmsMetastatic Renal Cell CarcinomaOvarian Clear Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell Carcinoma (RCC)
See CLDX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CLDX catalysts and pipeline →